Provided is
a peptide compound comprising the
amino acid sequence: Xaa1-Lys-Xaa3-Ser-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13 wherein: Xaa1 represents Ala or Ser, or is absent, wherein the N-terminal
amino acid optionally includes an N-terminal 3,4-dihydrocinnamic
acid group; Xaa5 represents Tyr, DOPA or a
single bond; Xaa3 and Xaa6 independently represent Pro, Hyp or diHyp; Xaa7, Xaa8, Xaa9, Xaa10, and Xaa11 are each optional (in which case Xaa6 is bonded to Xaa12), and are independently selected from the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Xaa12 represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Xaa13 represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said
peptide compound, provided that when the N-terminal 3,4-dihydrocinnamic
acid group is not present, Xaa1 represents Ala or is absent and Xaa13 represents Lys, then Xaa12 represents Pro, Hyp, diHyp or Thr. The compounds are particularly useful in for treatment of conditions characterised by
inflammation, including wounds, burns, and disorders of the mucosa, such as
anorectal diseases,
inflammatory bowel diseases, gynaecological diseases and dental diseases.